ArticleFrontiers in cellular and infection microbiology2022
Open access · goldAbstract read
In one paragraph
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Review
- The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets.Journal of fungi (Basel, Switzerland) · 2026Review
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2026Review
- Decoding resistance inFrontiers in cellular and infection microbiology · 2026Article
- The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis.Infection and drug resistance · 2026Review
- Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2025Review
- Understanding the mechanisms of resistance to azole antifungals inJAC-antimicrobial resistance · 2025Review
- Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods.JAC-antimicrobial resistance · 2025Article
- Characterization of Yeast Isolated from the Gut Microbiota of Tunisian Children with Autism Spectrum Disorder.Journal of fungi (Basel, Switzerland) · 2024Article
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
- A Mini-Review of In Vitro Data forJournal of fungi (Basel, Switzerland) · 2024Review
- Article
- Ibrexafungerp: A narrative overview.Current research in microbial sciences · 2024Review
- The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.Mycopathologia · 2023Review
- Insights and advances in recurrent vulvovaginal candidiasis.PLoS pathogens · 2023Article
- Intra-clade Heterogeneity in Candida auris: Risk of Management.Current microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 15 institutions in 6 countries.
Guillermo QuindósLaboratorio de Micología Médica, UFI 11/25, Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
Katherine Miranda-CadenaLaboratorio de Micología Médica, UFI 11/25, Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
Rosario San-MillánLaboratorio de Micología Médica, UFI 11/25, Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
Katyna Borroto-EsodaSCYNEXIS, Inc., Jersey City, NJ, United States.
Emilia CantónInstituto de Investigación Sanitaria, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
María José Linares-SiciliaResearch Group GC24, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Microbiology, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain.
Axel HamprechtUniversity Hospital Cologne, Cologne and Institute for Medical Microbiology and Virology, University of Oldenburg, Oldenburg, Germany.
Isabel MontesinosMicrobiology Department, LHUB-ULB, Hôpital Erasme, Brussels, Belgium.
Anna Maria TortoranoDipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy.
Anna PrigitanoDipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy.
Matxalen Vidal-GarcíaServicio de Microbiología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Cristina Marcos-AriasLaboratorio de Micología Médica, UFI 11/25, Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
Andrea GuridiLaboratorio de Micología Médica, UFI 11/25, Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
Ferran Sanchez-ReusServei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Jesús Machuca-BárcenaÁrea de Microbiología, Departamento de Biomedicina, Biotecnología y Salud Pública, Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain.
Manuel Antonio Rodríguez-IglesiasÁrea de Microbiología, Departamento de Biomedicina, Biotecnología y Salud Pública, Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain.
Estrella Martín-MazuelosServicio de Microbiología, Hospital Universitario de Valme, Sevilla, Spain.
Carmen Castro-MéndezServicio de Microbiología, Hospital Universitario de Valme, Sevilla, Spain.
Leyre López-SoriaServicio de Microbiología, Hospital Universitario de Cruces and BioCruces Bizkaia, Barakaldo, Spain.
Alba Ruiz-GaitánInstituto de Investigación Sanitaria, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Marcelo Fernandez-RiveroInstituto de Investigación Sanitaria, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Damaris LorenzoMicrobiology Unit, Medical School, Universitat Rovira i Virgili, Reus, Spain.
Javier CapillaMicrobiology Unit, Medical School, Universitat Rovira i Virgili, Reus, Spain.
Antonio RezustaServicio de Microbiología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Javier PemánInstituto de Investigación Sanitaria, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Josep GuarroMicrobiology Unit, Medical School, Universitat Rovira i Virgili, Reus, Spain.
Joana PereiraCentre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.
Célia PaisCentre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.
Orazio RomeoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Guillermo EzpeletaServicio de Microbiología, Complejo Hospitalario de Navarra, Pamplona and Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
Nerea JauregizarDepartamento de Farmacología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
David AnguloSCYNEXIS, Inc., Jersey City, NJ, United States.
Elena ErasoLaboratorio de Micología Médica, UFI 11/25, Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain.
University of the Basque Country · ESInstituto de Investigación Sanitaria La Fe · ESUniversidad Rovira i Virgili · ESHospital Universitario de Valme · ESHospital Universitario Miguel Servet · ESScynexis (United States) · USUniversidad de Cádiz · ESUniversity of Milan · ITUniversity of Minho · PTBioCruces Health research Institute · ESErasmus Hospital · BEHospital de Sant Pau · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversity Hospital Cologne · DEUniversity of Messina · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess the Methods: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for Conclusion: Ibrexafungerp showed a potent
Indexed as
Antifungal AgentsCandidiasis, InvasiveCandidaCandida albicansCandida glabrataCandida parapsilosisCandida tropicalisFluconazoleGlycosidesMicafunginTriterpenesAntifungal AgentsFluconazoleGlycosidesibrexafungerpMicafunginTriterpenesantifungal resistanceantifungal testingCandidacaspofunginEUCASTibrexafungerpmicafunginSCY-078
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.